ALLFTD is a comprehensive study targeting most varieties of FTLD. The overall goal of ALLFTD is to prepare for treatment trials in FTLD by focusing on several major activities: 1. Assemble a large group of well-characterized familial and sporadic FTLD patients evaluated at expert FTLD centers who can potentially be available for treatment trials 2 Collect comprehensive cognitive and behavioral data, in addition to imaging, blood and cerebrospinal fluid, with the following goals: a. Identify the best clinical and biomarker measures for following patients with FTLD in treatment trials b. Identify clinical measurements and biomarkers indicating that a person at high risk of FTLD due to a genetic mutation will begin to have symptoms in a predictable amount of time 3. Share clinical data, images and biological samples from participants affected by FTLD with the scientific community to address additional scientific questions about FTLD
|Effective start/end date||9/15/19 → 6/30/24|
- Mayo Clinic (NOR-263134-02//5U19AG063911-03)
- National Institute on Aging (NOR-263134-02//5U19AG063911-03)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.